A Comprehensive Review on Tuberculosis: Pathogenesis, Diagnosis, Drug Resistance, and Emerging Therapeutics

                                      Figure: Global Epidemiology and Burden of Tuberculosis

3. ETIOLOGY AND MICROBIOLOGICAL FEATURES:

Mycobacterium tuberculosis is an acid-fast, aerobic bacillus characterized by a lipid-rich cell wall containing mycolic acids. This unique structure provides resistance to environmental stress and many antimicrobial agents [21,22]. The organism exhibits slow growth, with a generation time significantly longer than most bacteria, which contributes to delays in diagnosis and treatment [23].  The pathogen possesses several virulence factors that enable intracellular survival, including inhibition of phagosome-lysosome fusion and modulation of host immune signaling pathways. These mechanisms allow the bacteria to persist within macrophages, leading to chronic infection and immune evasion. [24]. The etiological agent responsible for tuberculosis is Mycobacterium tuberculosis, a member of the Mycobacterium tuberculosis complex, which includes closely related species such as M. bovis, M. africanum, and M. microti. Among these, M. tuberculosis is the principal pathogen causing disease in humans. It is an obligate aerobic, non-motile, rod-shaped bacillus that exhibits distinctive staining properties due to its unique cell wall composition. The organism is classified as acid-fast, meaning it retains certain dyes such as carbol fuchsin even after treatment with acid-alcohol, a characteristic that forms the basis of Ziehl–Neelsen staining widely used in diagnostic microbiology. One of the most defining structural features of M. tuberculosis is its complex and lipid-rich cell envelope. Unlike typical Gram-positive or Gram-negative bacteria, the mycobacterial cell wall contains a high concentration of long-chain fatty acids known as mycolic acids, which are covalently linked to an underlying arabinogalactan-peptidoglycan complex. This highly hydrophobic barrier imparts several critical properties to the organism, including resistance to desiccation, chemical damage, and many antimicrobial agents. The cell wall also contains glycolipids such as lipoarabinomannan (LAM), which play a key role in modulating host immune responses. The impermeability of this lipid-rich envelope significantly limits the entry of many antibiotics, contributing to the intrinsic resistance of M. tuberculosis and necessitating prolonged multidrug therapy for effective treatment. In addition to its structural complexity, M. tuberculosis is characterized by its remarkably slow growth rate. The organism has a generation time of approximately 15–20 hours, which is considerably longer than that of most bacterial pathogens. This slow replication contributes to the chronic nature of tuberculosis and poses challenges for laboratory diagnosis, as culture-based methods may require several weeks to yield results. The slow metabolic activity of the bacillus also reduces its susceptibility to antibiotics that target actively dividing cells, further complicating treatment. Moreover, M. tuberculosis can enter a non-replicating or dormant state under unfavorable conditions, allowing it to persist within the host for extended periods without causing active disease. A critical aspect of the microbiological behavior of M. tuberculosis is its ability to survive and replicate within host macrophages, which are typically responsible for eliminating invading pathogens. Upon inhalation, the bacilli are engulfed by alveolar macrophages through phagocytosis. However, instead of being destroyed, M. tuberculosis employs multiple strategies to evade intracellular killing. One of the key mechanisms involves the inhibition of phagosome-lysosome fusion, preventing the formation of an acidic and enzyme-rich environment that would normally degrade the pathogen. By maintaining a relatively neutral pH within the phagosome, the bacteria create a favorable niche for survival and replication. The pathogen also produces a variety of virulence factors that contribute to its persistence and pathogenicity. These include proteins and lipids that interfere with host immune signaling pathways, thereby modulating the host response to infection. For instance, certain secreted proteins can inhibit the production of pro-inflammatory cytokines, reducing the effectiveness of the immune response. Additionally, components of the cell wall, such as lipoarabinomannan, can alter macrophage activation and impair antigen presentation, further aiding in immune evasion. These interactions highlight the sophisticated strategies employed by M. tuberculosis to establish a long-term presence within the host. Another important feature of M. tuberculosis is its metabolic adaptability. The bacterium can utilize a wide range of carbon sources, including lipids and fatty acids, which are abundant within host cells. During infection, M. tuberculosis shifts its metabolism to exploit host-derived lipids, enabling it to survive in nutrient-limited environments such as granulomas. This metabolic flexibility is closely associated with the ability of the organism to enter a dormant state, characterized by reduced metabolic activity and increased resistance to stress. Dormant bacilli are less susceptible to conventional antibiotics, which primarily target actively growing cells, thereby contributing to the persistence of infection and the risk of reactivation. The genetic makeup of M. tuberculosis also plays a significant role in its pathogenicity. The genome of the bacterium is relatively large and encodes numerous genes involved in lipid metabolism, stress response, and virulence. Genetic variations among different strains can influence factors such as transmissibility, disease severity, and drug resistance. For example, mutations in genes encoding drug targets or activating enzymes can lead to resistance against first-line anti-tubercular drugs such as isoniazid and rifampicin. Understanding these genetic mechanisms is essential for the development of new diagnostic tools and therapeutic strategies. Environmental resilience is another characteristic that contributes to the epidemiological success of M. tuberculosis. Although the organism is sensitive to ultraviolet light and heat, it can survive for extended periods in dark and moist environments. This ability enhances its potential for transmission in crowded indoor settings where ventilation is poor. However, unlike many other pathogens, M. tuberculosis does not multiply outside the host, and its survival in the environment primarily serves as a means of maintaining infectivity rather than replication. Furthermore, the interaction between M. tuberculosis and the host immune system is dynamic and complex. The initial immune response involves innate mechanisms, including the activation of macrophages and dendritic cells. This is followed by the development of adaptive immunity, particularly the activation of T-helper 1 (Th1) cells, which produce interferon-gamma to enhance macrophage killing. Despite these responses, M. tuberculosis often succeeds in establishing a balance between bacterial survival and host defense, resulting in the formation of granulomas. These structures, while protective in limiting bacterial spread, also provide a niche for bacterial persistence. In summary, the etiological and microbiological characteristics of to Mycobacterium tuberculosis are central to its success as a pathogen. Its unique cell wall structure, slow growth rate, metabolic adaptability, and sophisticated immune evasion strategies enable it persist within the host and cause chronic infection. These features not only complicate diagnosis and treatment but also contribute to the global burden of tuberculosis. A detailed understanding of these properties is essential for the development of more effective diagnostic tools, therapeutic agents, and preventive strategies aimed at controlling and ultimately eliminating this enduring disease [25].

4. PATHOGENESIS AND HOST IMMUNE RESPONSE:

The pathogenesis of tuberculosis begins with inhalation of infectious droplet nuclei containing M. tuberculosis. Upon reaching the alveoli, the bacteria are engulfed by macrophages. In many cases, the host immune system mounts a cell-mediated response involving T lymphocytes and cytokines such as interferon-gamma and tumor necrosis factor-alpha.  This immune response leads to the formation of granulomas, which serve to contain the infection. However, in individuals with weakened immunity, the bacteria proliferate, resulting in active disease characterized by tissue destruction and cavitation. Latent tuberculosis infection represents a state in which the bacteria remain dormant within granulomas, with the potential for reactivation under conditions of immune suppression. Recent studies highlight the heterogeneity of host responses, emphasizing that factors such as age, co-morbidities, and genetic predisposition influence disease progression and treatment outcomes. The pathogenesis of tuberculosis is a complex, multistep process that involves intricate interactions between Mycobacterium tuberculosis and the host immune system. Infection begins when aerosolized droplet nuclei containing viable bacilli are inhaled and deposited in the alveolar spaces of the lungs. At this initial stage, alveolar macrophages serve as the first line of defense by recognizing and engulfing the bacteria through phagocytosis. However, instead of being eliminated, M. tuberculosis has evolved mechanisms to survive within these cells by inhibiting phagosome-lysosome fusion and resisting intracellular killing. This allows the pathogen to replicate within macrophages and establish an early infection focus. The host immune response plays a critical role in determining the outcome of infection. Within a few weeks, antigen-presenting cells such as macrophages and dendritic cells migrate to regional lymph nodes, where they activate T lymphocytes, particularly CD4+ T-helper cells. These activated T cells release cytokines, including interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which enhance the antimicrobial activity of macrophages. This cell-mediated immune response is essential for controlling bacterial replication and limiting the spread of infection. Additionally, CD8+ T cells contribute by directly killing infected cells and releasing cytotoxic molecules. One of the hallmark features of tuberculosis pathogenesis is the formation of granulomas, which are organized aggregates of immune cells that serve to contain the infection. Granulomas typically consist of a central core of infected macrophages, including specialized forms such as epithelioid cells and multinucleated giant cells, surrounded by a layer of lymphocytes and a fibrotic capsule. While granuloma formation is a protective mechanism that restricts bacterial dissemination, it also provides a niche in which M. tuberculosis can persist in a dormant state. Within this environment, the bacteria can enter a non-replicating phase characterized by reduced metabolic activity, allowing them to evade immune clearance and resist antibiotic treatment. The progression from latent infection to active disease is influenced by the balance between bacterial virulence and host immunity. In individuals with a robust immune response, the infection is effectively contained, resulting in latent tuberculosis infection, which is asymptomatic and non-transmissible. However, when the immune system is compromised, the integrity of granulomas may be disrupted, leading to bacterial reactivation and active disease. This is often associated with caseous necrosis, tissue destruction, and the formation of cavities within the lungs, which facilitate the release of bacilli into the airways and enhance transmission. Host-related factors play a significant role in modulating the immune response to M. tuberculosis. Conditions such as HIV infection, diabetes mellitus, malnutrition, and aging can impair immune function and increase susceptibility to active disease. Genetic variations in immune response genes have also been implicated in influencing individual susceptibility and disease severity. Furthermore, environmental factors, including exposure intensity and duration, contribute to variations in disease outcomes. Recent research has highlighted the heterogeneity of host immune responses, suggesting that differences in cytokine profiles, immune cell activation, and inflammatory pathways can significantly impact disease progression and treatment outcomes. the pathogenesis of tuberculosis is governed by a dynamic interplay between the pathogen and the host immune system. While the immune response is essential for controlling infection, it also contributes to tissue damage and disease pathology. Understanding these mechanisms is crucial for the development of improved therapeutic strategies, including host-directed therapies aimed at enhancing protective immunity while minimizing immunopathology [26].

Figure 2: Pathogenesis of Tuberculosis

5. Clinical Manifestations:

Tuberculosis presents with a wide spectrum of clinical manifestations depending on the site of infection and immune status of the host. Pulmonary TB is the most common form and typically presents with chronic cough, sputum production, hemoptysis, fever, night sweats, and weight loss.   Extrapulmonary TB can affect various organs, including lymph nodes, pleura, bones, and the central nervous system. These forms often present with non-specific symptoms, making diagnosis more challenging. The diversity in clinical presentation contributes to delays in diagnosis and increases the risk of disease transmission [27].

Table:1 Clinical Manifestations of Tuberculosis: [28,29].

6. DIAGNOSTIC ADVANCES:

Accurate diagnosis of tuberculosis is critical for effective disease management. Traditional diagnostic methods such as sputum smear microscopy and culture remain widely used, although they have limitations in sensitivity and turnaround time [30]. Recent advancements in molecular diagnostics, including nucleic acid amplification tests, have significantly improved the speed and accuracy of TB detection. These methods can also identify drug resistance mutations, enabling early initiation of appropriate therapy. Emerging technologies such as artificial intelligence-based screening using cough sound analysis and imaging techniques have shown promising results in improving early detection, particularly in resource-limited settings [31]. Despite significant progress in global health initiatives, diagnostic delays continue to contribute to ongoing transmission and poor clinical outcomes. Traditionally, methods such as sputum smear microscopy and culture-based techniques have served as the foundation of tuberculosis diagnosis. While smear microscopy is rapid and inexpensive, its sensitivity is limited, particularly in cases with low bacterial load, such as pediatric and extrapulmonary tuberculosis. Culture methods, although considered the gold standard due to their high sensitivity and ability to detect viable organisms, are time-consuming and may require several weeks to yield results, thereby delaying treatment initiation. In recent years, the diagnostic landscape of tuberculosis has undergone a transformative shift with the introduction of molecular technologies. Nucleic acid amplification tests (NAATs), including cartridge-based systems, have revolutionized the detection of Mycobacterium tuberculosis by enabling rapid identification of bacterial DNA directly from clinical samples. These techniques not only provide results within a few hours but also offer improved sensitivity compared to conventional methods. Importantly, many molecular platforms are capable of simultaneously detecting genetic mutations associated with drug resistance, particularly resistance to rifampicin, which serves as a key marker for multidrug-resistant tuberculosis. This advancement allows clinicians to initiate targeted therapy at an earlier stage, significantly improving patient outcomes and reducing transmission. Beyond molecular diagnostics, immunological assays have also contributed to improved detection of tuberculosis infection. Interferon-gamma release assays (IGRAs) and tuberculin skin tests are commonly used to identify latent tuberculosis infection. While these tests are valuable for screening purposes, they do not differentiate between active and latent disease, highlighting the need for complementary diagnostic approaches. Emerging diagnostic innovations are further enhancing the ability to detect tuberculosis in diverse clinical settings. Advances in imaging technologies, including digital chest radiography and computed tomography, have improved the visualization of disease patterns, particularly in cases where microbiological confirmation is challenging. The integration of artificial intelligence (AI) into radiological analysis has demonstrated significant potential in automating the detection of characteristic TB lesions, thereby reducing diagnostic variability and supporting healthcare providers in resource-constrained environments. In addition to imaging, novel AI-driven tools are being developed to analyze cough sounds for early detection of tuberculosis. These non-invasive approaches leverage machine learning algorithms to identify acoustic patterns associated with the disease, offering a rapid and accessible screening method. Such innovations are particularly valuable in remote or underserved regions where access to advanced laboratory infrastructure is limited.  Furthermore, biomarker-based diagnostics are gaining attention as potential tools for early and accurate detection. Research into host-derived biomarkers, including specific proteins, metabolites, and gene expression signatures, aims to distinguish between active and latent infection as well as predict disease progression. Although many of these approaches are still under investigation, they hold promise for the development of point-of-care diagnostic tests that are both rapid and highly accurate. In conclusion, the evolution of tuberculosis diagnostics reflects a shift toward rapid, sensitive, and decentralized testing strategies. The integration of molecular tools, artificial intelligence, and biomarker research represents a significant advancement in the fight against tuberculosis. However, ensuring equitable access to these technologies remains a critical challenge. Strengthening diagnostic capacity, particularly in high-burden regions, will be essential for achieving global tuberculosis control and elimination goals [32].

Figure 3: Diagnostic Algorithm for Tuberculosis

7. TREATMENT AND PHARMACOLOGICAL MANAGEMENT:

The treatment of tuberculosis involves prolonged multidrug therapy to ensure complete eradication of the pathogen and prevent resistance. Standard first-line therapy includes isoniazid, rifampicin, pyrazinamide, and ethambutol administered over a six-month period.  Adherence to treatment is essential, as incomplete or irregular therapy can lead to relapse and the development of drug-resistant strains. Public health strategies such as directly observed treatment have been implemented to improve adherence and treatment outcomes. The management of tuberculosis is based on a comprehensive therapeutic approach that combines prolonged multidrug chemotherapy with supportive public health interventions. The primary objective of treatment is to achieve complete eradication of Mycobacterium tuberculosis, prevent disease relapse, interrupt transmission, and minimize the emergence of drug resistance. Due to the slow-growing nature of the pathogen and its ability to persist in a dormant state within host tissues, extended treatment regimens are required to ensure effective bacterial clearance. Standard treatment for drug-susceptible tuberculosis involves a combination of first-line antitubercular drugs administered over a period of at least six months. This regimen is divided into two phases: an intensive phase and a continuation phase. The intensive phase typically lasts for two months and includes four drugs—isoniazid, rifampicin, pyrazinamide, and ethambutol. This phase is aimed at rapidly reducing the bacterial load and controlling active disease. The continuation phase, which follows for an additional four months, generally includes isoniazid and rifampicin to eliminate residual bacilli and prevent relapse [33]. Each of these first-line drugs possesses a distinct mechanism of action that contributes to the overall effectiveness of the regimen. Isoniazid inhibits the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall. Rifampicin acts by inhibiting bacterial RNA polymerase, thereby suppressing transcription. Pyrazinamide is particularly effective in acidic environments, targeting semi-dormant bacilli within macrophages. Ethambutol interferes with cell wall synthesis by inhibiting arabinosyl transferase enzymes. The use of combination therapy is critical, as it reduces the likelihood of the bacteria developing resistance to any single agent. Adherence to the prescribed treatment regimen is a crucial determinant of therapeutic success. Incomplete or irregular therapy can lead to treatment failure, relapse, and the emergence of drug-resistant forms of tuberculosis, such as multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. To address these challenges, public health strategies such as directly observed treatment (DOT) have been widely implemented. Under this approach, healthcare providers or trained personnel supervise patients during drug administration to ensure compliance and monitor for adverse effects. The management of drug-resistant tuberculosis is more complex and requires the use of second-line drugs, which are often less effective, more toxic, and more expensive. These regimens may include fluoroquinolones, injectable agents, and newer drugs such as bedaquiline and delamanid. Treatment duration for drug-resistant TB is significantly longer, often extending to 9–24 months depending on the resistance pattern and patient response. The introduction of shorter, all-oral regimens has shown promise in improving patient adherence and outcomes. Adverse drug reactions are an important consideration in tuberculosis therapy and may affect treatment adherence. Common side effects include hepatotoxicity, peripheral neuropathy, gastrointestinal disturbances, and visual impairment. Regular monitoring and early detection of adverse effects are essential to ensure patient safety and continuity of therapy. Additionally, special populations such as children, pregnant women, and individuals with co-morbid conditions require tailored treatment approaches to optimize efficacy and minimize risks. Recent advances in tuberculosis pharmacotherapy have focused on the development of shorter, more effective regimens and the incorporation of novel agents. Research into host-directed therapies aims to enhance the immune response and improve treatment outcomes. Furthermore, fixed-dose combination formulations have been introduced to simplify treatment regimens and reduce pill burden, thereby improving patient adherence. In conclusion, the pharmacological management of tuberculosis requires a multifaceted approach that integrates effective drug therapy, patient adherence strategies, and ongoing monitoring. Continued innovation in drug development and treatment strategies is essential to address the challenges posed by drug resistance and to achieve global tuberculosis control [34].

Table: Antitubercular Drugs and Their Characteristics [35].

8. DRUG-RESISTANT TUBERCULOSIS:

Drug resistance represents one of the most significant challenges in TB control. Multidrug-resistant TB is defined by resistance to isoniazid and rifampicin, while extensively drug-resistant TB includes resistance to additional second-line drugs. Recent regional data indicate increasing trends in drug resistance, with significant proportions of cases showing resistance to at least one anti-TB drug. The emergence of resistance is primarily driven by inadequate treatment, poor adherence, and improper drug use. Molecular mechanisms of resistance involve genetic mutations in drug target genes, which reduce drug efficacy and complicate treatment. Drug-resistant Tuberculosis has emerged as one of the most formidable obstacles to global tuberculosis control, threatening decades of progress in disease management. Resistance to anti-tubercular drugs compromises treatment efficacy, prolongs infectiousness, increases healthcare costs, and contributes significantly to morbidity and mortality. The growing burden of resistant tuberculosis highlights the urgent need for improved diagnostic strategies, effective treatment regimens, and robust public health interventions. Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to at least isoniazid and rifampicin, the two most potent first-line drugs. Extensively drug-resistant tuberculosis (XDR-TB) represents a more severe form, characterized by additional resistance to key second-line agents, including fluoroquinolones and certain injectable drugs. More recently, the concept of pre-XDR TB has been introduced to describe strains with resistance to rifampicin and any fluoroquinolone, reflecting the evolving complexity of resistance patterns. These classifications underscore the progressive nature of drug resistance and its implications for treatment outcomes. The emergence and spread of drug-resistant tuberculosis are driven by multiple interrelated factors. Inadequate or incomplete treatment remains the most significant contributor, often resulting from poor patient adherence, suboptimal drug regimens, or interruptions in drug supply. Misuse of antibiotics, including incorrect dosing and inappropriate prescription practices, further accelerates the development of resistance. Additionally, healthcare system limitations, such as insufficient diagnostic capacity and delayed detection of resistance, contribute to ongoing transmission of resistant strains within communities. At the molecular level, drug resistance in Mycobacterium tuberculosis primarily arises through spontaneous genetic mutations in specific genes encoding drug targets or drug-activating enzymes. For instance, resistance to rifampicin is commonly associated with mutations in the rpoB gene, which encodes the beta subunit of RNA polymerase. Similarly, mutations in the katG gene or the inhA promoter region are linked to isoniazid resistance, affecting the activation or target binding of the drug [36,37]. Fluoroquinolone resistance is typically mediated by mutations in the gyrA and gyrB genes, while resistance to injectable agents may involve alterations in ribosomal components or associated pathways. These genetic changes reduce drug binding or activation, thereby diminishing therapeutic efficacy. The clinical implications of drug-resistant tuberculosis are profound. Patients with resistant forms of the disease often require prolonged treatment with second-line or newer drugs, which are generally less effective, more toxic, and more expensive than first-line therapies. Treatment duration may extend from several months to over a year, placing a significant burden on both patients and healthcare systems. Furthermore, adverse drug reactions are more frequent and severe in resistant TB regimens, leading to challenges in maintaining adherence and achieving successful outcomes. Recent advances in molecular diagnostics have improved the detection of drug resistance, enabling rapid identification of resistance-associated mutations. Techniques such as line probe assays and next-generation sequencing allow for early diagnosis and tailored treatment strategies. These tools are particularly valuable in high-burden settings, where timely detection of resistance can prevent the spread of resistant strains and improve patient prognosis. From a public health perspective, controlling drug-resistant tuberculosis requires a multifaceted approach. Strengthening treatment adherence through patient-centered care models, ensuring uninterrupted drug supply, and implementing effective infection control measures are critical components. Surveillance systems must be enhanced to monitor resistance trends and guide policy decisions. Additionally, ongoing research into novel therapeutics and shorter treatment regimens offers hope for more effective management of resistant TB in the future. In conclusion, drug-resistant tuberculosis represents a complex and evolving challenge that demands coordinated efforts at both clinical and public health levels. Addressing the underlying causes of resistance, improving diagnostic capabilities, and advancing treatment options are essential for reducing the global burden of this disease. Without sustained and comprehensive interventions, drug-resistant tuberculosis will continue to undermine global efforts toward tuberculosis elimination [38].

Figure 4: Mechanisms of Drug Resistance

Table 2:  Type of Drug Resistance Tuberculosis:

9. PREVENTION AND CONTROL STRATEGIES:

Effective TB control requires a combination of medical and public health interventions. Vaccination with Bacillus Calmette–Guérin provides partial protection, particularly in children. Early detection and prompt treatment are critical in reducing transmission. Public health initiatives focusing on awareness, screening, and improved living conditions play a vital role in disease control. The WHO End TB Strategy emphasizes the need for integrated approaches combining healthcare delivery, research, and social interventions. The prevention and control of tuberculosis require a coordinated and multifaceted approach that integrates clinical management with robust public health interventions. Given the airborne nature of transmission and the complex interplay of biological and social determinants, effective control strategies must address both the source of infection and the conditions that facilitate disease spread. Over the years, global efforts have evolved from isolated treatment-focused approaches to comprehensive frameworks that emphasize prevention, early detection, and sustained community engagement. Vaccination remains one of the earliest and most widely implemented preventive measures against tuberculosis. The Bacillus Calmette–Guérin (BCG) vaccine has been extensively used for decades, particularly in countries with a high burden of disease. While BCG provides variable protection against pulmonary tuberculosis in adults, it is highly effective in preventing severe forms of the disease in children, such as miliary tuberculosis and tuberculous meningitis. Despite its limitations, BCG continues to play a crucial role in national immunization programs. Ongoing research is focused on developing more effective vaccines that can provide long-lasting immunity across all age groups, with several candidates currently in different stages of clinical trials. Early detection and prompt initiation of appropriate treatment are central to interrupting the chain of transmission. Active case finding, particularly among high-risk populations, has emerged as an important strategy to identify undiagnosed cases. Screening programs in vulnerable groups—such as individuals with HIV infection, close contacts of TB patients, and those living in overcrowded settings—facilitate early diagnosis and reduce the likelihood of disease progression and spread. The integration of advanced diagnostic tools, including molecular testing and digital radiography, has further enhanced the efficiency of screening and case detection. Treatment of active cases not only benefits the individual patient but also serves as a critical public health intervention by reducing infectiousness. Ensuring treatment adherence through patient-centered approaches is essential for achieving successful outcomes and preventing the development of drug resistance. Strategies such as directly observed therapy, digital adherence technologies, and community-based support systems have been implemented to improve compliance. In addition, preventive therapy for individuals with latent tuberculosis infection, particularly those at high risk of progression to active disease, represents an important component of control efforts. Public health initiatives play a pivotal role in addressing the broader determinants of tuberculosis transmission. Awareness campaigns aimed at educating communities about the symptoms, modes of transmission, and availability of treatment can reduce stigma and encourage early healthcare seeking behavior. Improving living conditions, including reducing overcrowding and enhancing ventilation in homes and workplaces, significantly decreases the risk of airborne transmission. Nutritional support programs are also important, as malnutrition weakens immune function and increases susceptibility to infection. The global response to tuberculosis is guided by comprehensive frameworks such as the End TB Strategy proposed by the World Health Organization. This strategy outlines ambitious targets for reducing TB incidence and mortality through a combination of integrated healthcare services, strengthened health systems, and intensified research and innovation. Key pillars of the strategy include patient-centered care, bold policies addressing social determinants, and the promotion of new tools such as vaccines, diagnostics, and therapeutics. Collaboration between governments, healthcare providers, researchers, and communities is essential to achieve these goals. In addition to traditional approaches, innovative technologies are increasingly being incorporated into tuberculosis control programs. Digital health platforms enable real-time monitoring of treatment adherence and facilitate communication between patients and healthcare providers. Artificial intelligence-based tools are being used to enhance screening and diagnostic accuracy, particularly in resource-limited settings. These advancements offer new opportunities to improve the efficiency and reach of TB control efforts. In conclusion, the prevention and control of tuberculosis require sustained commitment and a holistic approach that combines medical, social, and technological interventions. While significant progress has been made, challenges such as drug resistance, healthcare disparities, and socioeconomic inequalities continue to hinder global efforts. Strengthening prevention strategies, expanding access to care, and fostering innovation will be critical to achieving long-term control and eventual elimination of tuberculosis [39].

Figure 5: Prevention and Control Strategy Framework